OBJECTIVE: Data suggest the involvement of serotonergic and neurotrophic systems in major depressive disorder. To investigate their potential interaction, the authors studied changes in serum levels of brain-derived neurotrophic factor (BDNF) during tryptophan depletion and sham depletion in unmedicated patients with remitted major depressive disorder and in a group of healthy comparison subjects. METHOD: Twenty-seven patients with remitted major depressive disorder and 20 healthy subjects underwent tryptophan depletion and sham depletion in a randomized, placebo-controlled, double-blind crossover study. Serum BDNF concentrations and plasma tryptophan concentrations as well as behavioral assessments were obtained. RESULTS: During tryptophan depletion, BDNF levels increased in healthy volunteers. By contrast, patients with remitted major depressive disorder were unable to mount this presumed compensatory response, and BDNF levels remained low in these patients. CONCLUSIONS: The results further substantiate the potential role of BDNF in major depressive disorder.
RCT Entities:
OBJECTIVE: Data suggest the involvement of serotonergic and neurotrophic systems in major depressive disorder. To investigate their potential interaction, the authors studied changes in serum levels of brain-derived neurotrophic factor (BDNF) during tryptophan depletion and sham depletion in unmedicated patients with remitted major depressive disorder and in a group of healthy comparison subjects. METHOD: Twenty-seven patients with remitted major depressive disorder and 20 healthy subjects underwent tryptophan depletion and sham depletion in a randomized, placebo-controlled, double-blind crossover study. Serum BDNF concentrations and plasma tryptophan concentrations as well as behavioral assessments were obtained. RESULTS: During tryptophan depletion, BDNF levels increased in healthy volunteers. By contrast, patients with remitted major depressive disorder were unable to mount this presumed compensatory response, and BDNF levels remained low in these patients. CONCLUSIONS: The results further substantiate the potential role of BDNF in major depressive disorder.
Authors: Francisco A Moreno; Damian Parkinson; Craig Palmer; Wm Lesley Castro; John Misiaszek; Aram El Khoury; Aleksander A Mathé; Ron Wright; Pedro L Delgado Journal: Eur Neuropsychopharmacol Date: 2010-01 Impact factor: 4.600
Authors: John J B Allen; Katherine M McKnight; Francisco A Moreno; Heath A Demaree; Pedro L Delgado Journal: J Affect Disord Date: 2008-09-18 Impact factor: 4.839
Authors: Abigail A Marsh; Elizabeth C Finger; Beata Buzas; Niveen Soliman; Rebecca A Richell; Meena Vythilingham; Daniel S Pine; David Goldman; R J R Blair Journal: Psychopharmacology (Berl) Date: 2006-09-30 Impact factor: 4.530
Authors: Richard Whale; Felix Beacher; Bruno Golding; Paul Gard; Hugo Critchley Journal: Psychopharmacology (Berl) Date: 2010-05-01 Impact factor: 4.530
Authors: Lara G Chepenik; Carolyn Fredericks; Xenophon Papademetris; Linda Spencer; Cheryl Lacadie; Fei Wang; Brian Pittman; James S Duncan; Lawrence H Staib; Ronald S Duman; Joel Gelernter; Hilary P Blumberg Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Francisco A Moreno; Robert P Erickson; Holly A Garriock; Joel Gelernter; Jim Mintz; Jennifer Oas-Terpstra; Marilyn A Davies; Pedro L Delgado Journal: Mol Neuropsychiatry Date: 2015-09-24
Authors: Andreas Baranyi; Andreas Meinitzer; Hans-Bernd Rothenhäusler; Omid Amouzadeh-Ghadikolai; Dirk V Lewinski; Robert J Breitenecker; Markus Herrmann Journal: PLoS One Date: 2018-11-29 Impact factor: 3.240
Authors: Andreas Baranyi; Andreas Meinitzer; Robert J Breitenecker; Omid Amouzadeh-Ghadikolai; Rudolf Stauber; Hans-Bernd Rothenhäusler Journal: PLoS One Date: 2015-09-14 Impact factor: 3.240